mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan… - Signal transduction and …, 2022 - nature.com
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
COVID-19 vaccine development: milestones, lessons and prospects
M Li, H Wang, L Tian, Z Pang, Q Yang… - Signal transduction and …, 2022 - nature.com
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in
England starting on 14 September 2021. We used a test-negative case–control design to …
England starting on 14 September 2021. We used a test-negative case–control design to …
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.
1.617. 2) variant and potential waning immunity in observed reductions in effectiveness …
1.617. 2) variant and potential waning immunity in observed reductions in effectiveness …
Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
Where 2020 saw the development and testing of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022 - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 …
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 …
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA
vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory …
vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory …
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Emerging reports of rare neurological complications associated with COVID-19 infection and
vaccinations are leading to regulatory, clinical and public health concerns. We undertook a …
vaccinations are leading to regulatory, clinical and public health concerns. We undertook a …